About the Bing Center for Waldenström's Macroglobulinemia
The Bing Center for Waldenström's Macroglobulinemia (WM) is the largest center in the world that is dedicated to the study and development of new, targeted treatments for WM and related Immunoglobulin M (IgM) disorders including IgM related neuropathy, and Bing Neel Syndrome. The Center is credited with the discovery of the MYD88 and CXCR4 mutations in WM, the approval of the first ever drug for WM (ibrutinib), and advancement of numerous new drugs for WM through clinical trials.
The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:
• Evaluations and ongoing clinical care
• Consultations (Second Opinions)
• Genomic Testing for WM relevant mutations including MYD88, CXCR4 and TP53
• Pathology review of biopsy samples
• Development of a personalized treatment plan offering the latest therapies (chemotherapy, biological and immune therapies)
• Access to clinical trials offering novel treatments
• Participation in laboratory studies including studies focused on WM genomics and new drug discovery
• Stem cell transplantation
• Complementary therapies through the Leonard P. Zakim Center for Integrative Therapies and Healthy Living
Waldenstrom's Macroglobulinemia Clinic
The Waldenstrom's Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
For more information on the WM Clinic at DFCI, please visit the DFCI Center for Hematologic-Oncology/Waldenstrom's Macroglobulinemia Clinic.
Basic Research
Waldenström’s macroglobulinemia (WM) is a distinct B-cell malignancythat results from the accumulation, predominantly in the bone marrow, of clonally related B type lymphocytes, lymphoplasmacytic cells and plasma cells which secrete a monoclonal IgM protein.1 This condition is considered to correspond to the lymphoplasmacytic lymphoma (LPL) as defined by the World Health Organization classification system.2 Most cases of LPL are WM, with less than 5% of cases made up of IgA, IgG and non-secreting LPL ...
Latest Bing Center News
Waldenstrom: Reaching the Relapsed Refractory Stage
Waldenstrom Macroglobulinemia (WM) is not curable, which means most patients will either reach the relapsed or refractory stage at some point in their journey. Patient Power spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what reaching these stages mean for WM patients.
Waldenstrom Macroglobulinemia: Who Gets What and When?
As many as 50% of people at the time of their Waldenstrom macroglobulinemia (WM) diagnosis won’t need drug therapy for a number of years. We spoke with Shayna Sarosiek, MD, hematologist/oncologist from at the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute in Boston, to share what “supportive treatments” could help in the meantime.
We want YOU to join our Jimmy FundRaiser community!
We want YOU to join our Jimmy FundRaiser community! The Dana-Farber Community Fundraising Event (CFE) program is where community members hold their own fundraisers or events on behalf of Dana-Farber and the Jimmy Fund. Fundraisers range from bake sales to hiking mountains, walking a 5k, and holding a virtual cooking class. Holding a fundraiser can be an outlet for individuals or families who want to take an “action” towards supporting a loved one, remembering a loved one, or fighting their own fight against cancer.
Zachary Hunter - 20 Years at Dana-Farber!
I first met Zach in 2004 when I joined the Bing Center as a volunteer. He was managing clinical trials, and immediately became my "go-to" person when I needed help or advice on any technical issue. Zach created the first WM Workshop website, and then taught me how to maintain it. I was able to build on that knowledge to create other websites.
What insights can multi-omics provide into the mechanism of disease progression in WM?
On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Zachary Hunter, Dana-Farber Cancer Institute, Boston, US. We asked, What insights can multi-omics provide into the mechanism of disease progression in Waldenstrom’s macroglobulinemia (WM)?
My Waldenström Macroglobulinemia, Miracle Number Three
Dear Fellow Cancer Patient: As I believe in universal love for ALL, I’m reaching out to you, whether we have met or not, to invite you to join me in embracing the concept of medical miracles no matter what kind of cancer you have.
Update on Bing Neel Syndrome - Shayna Sarosiek April, 2023
From Bing-Neel Co-Leader & Lifeline Volunteer, Julie Davidson: "The Bing-Neel Support Group just had our Spring meeting. We featured a wonderfully informative video by Dr. Shayna Sarosiek, senior physician at the Dana-Farber Cancer Institute’s Bing Center for Waldenstrom’s Macroglobulinemia.
2022 March Dr. Treon "Rounds" with Canadian Medical Professionals
We invited Canadian medical professionals to listen to Dr. Treon of the DFCI. (There were 2 sessions - EST & PST) He provided a very thorough update on the state of WM and its treatment.
IWWM-11 (Madrid 2022) Consensus Panel Reports
Consensus panel reports from the 11th International Workshop on Waldenstrom's Macroglobulinemia.
Dana-Farber Researchers Use Machine Learning to Understand Rare Familial Blood Cancer
Researchers at Dana-Farber have put together a data atlas that includes a range of genomic, transcriptomic, epigenetic, and clinical data from patients and healthy donors to try to understand familial WM.